Envoy Medical, Inc. (COCH) Form 8-K — Aug 10, 2026
Envoy Medical reported Q2 2026 results with net revenue of $51 thousand and a net loss attributable to common stockholders of $7,272 thousand, or $0.07 per basic and diluted share, versus a $6,942 thousand loss a year earlier. The company submitted the first of four modules of its Modular PMA application to the FDA for the investigational fully implanted Acclaim cochlear implant, with the fourth and final module targeted for the second quarter of 2027.
Key figures
- Revenue
- 51000
- Net Income
- Net loss of $5,982 thousand; net loss attributable to common stockholders of $7,272 thousand (vs $6,942 thousand in Q2 2025)
- Revenue Yoy
- Down from $78 thousand in Q2 2025 to $51 thousand in Q2 2026
- Total Assets
- 23949000
- Cash Position
- 19679000
- Shares Outstanding
- 77194595
- Cogs q2 2026
- 278000
- Improvement 12mo
- 38.0 percentage points
- Pma modules total
- 4
- Ga expense q2 2026
- 2029000
- Rd expense q2 2025
- 2485000
- Rd expense q2 2026
- 3132000
- Improvement 6mo prior
- 24.0 percentage points
- Atm program terminated
- 15000000
- Final pma module target
- Q2 2027
- Cnc baseline pre implant
- 15.2%
- Six month offering costs
- 2215000
- Cnc word recognition 12mo
- 53.2%
- Shares outstanding dec 2025
- 28934960
- Sales marketing expense q2 2026
- 181000
- Six month offering gross proceeds
- 29997000
Price after filing
1 day: 0.0%7 days: +9.5%30 days: +5.9%
Close on the filing date to close N calendar days later (from $0.67). Historical, not a forecast.
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.